Recent research milestones include the landmark FDA approval of beremagene geperpavec (B-VEC), the first topical gene therapy for the rare skin disease epidermolysis bullosa, offering profound wound healing benefits for affected patients. Concurrently, innovative oncolytic virus and immunotherapy synergies have emerged as promising cancer treatments, selectively targeting tumor cells while activating immune responses. MD Anderson Cancer Center and Phoenix SENOLYTIX announced a strategic global cross-licensing partnership to advance inducible safety switch technologies, aiming at enhanced efficacy and safety in cell and gene therapies.